The Market Herald Interview Discussing First-of-its-Kind Magnetic Imaging Technology
We recently announced that our MagSense® diagnostic technology has the potential to target prostate cancer tumors, making this the second cancer type the…
Imagion to Present Prostate Cancer Research Data at WMIC 2022
Imagion to present prostate cancer research data at World Molecular Imaging Congress MagSense® molecular imaging agent shows high specificity and selectivity……
MagSense Technology Animation
. Cancer treatments are most effective, and patient outcomes are improved, when tumors are detected early. Imagion Biosystems is developing the MagSense®…
MagSense Technology Leading a Broad Trend in Cancer Medicine
This article represents the viewpoint of management. MagSense® technology is taking a leading position amidst a broad trend in cancer medicine toward finding…
Investor Update — Corporate Presentation Visuals
Imagion Biosystems has updated investors by lodging the latest version of its corporate presentation visuals with the Australian Securities Exchange. Content…
Magnetic Relaxometry for Cancer Detection
In this second segment of Bob Proulx's presentation to investors at the 2016 NobleCon meeting, he answers the question of how magnetic relaxometry might be…
Company Overview Presentation
click image to download pdf file Here are the principal "slide deck" visuals used to introduce Imagion Biosystems to investors prior to the company's initial…
Earlier Detection Means An Earlier Cure
Data from the US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program, charted below, illustrates the critical importance of…